Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Cash (2023 - 2025)

Contineum Therapeutics has reported Change in Cash over the past 3 years, most recently at $33.0 million for Q4 2025.

  • Quarterly results put Change in Cash at $33.0 million for Q4 2025, up 274.0% from a year ago — trailing twelve months through Dec 2025 was $53.7 million (up 736.22% YoY), and the annual figure for FY2025 was $53.7 million, up 736.22%.
  • Change in Cash for Q4 2025 was $33.0 million at Contineum Therapeutics, up from $21.8 million in the prior quarter.
  • Over the last five years, Change in Cash for CTNM hit a ceiling of $61.0 million in Q2 2024 and a floor of -$36.3 million in Q3 2024.
  • Median Change in Cash over the past 3 years was $632500.0 (2024), compared with a mean of $5.8 million.
  • Biggest five-year swings in Change in Cash: tumbled 849.77% in 2024 and later soared 274.0% in 2025.
  • Contineum Therapeutics' Change in Cash stood at -$2.0 million in 2023, then tumbled by 849.77% to -$18.9 million in 2024, then soared by 274.0% to $33.0 million in 2025.
  • The last three reported values for Change in Cash were $33.0 million (Q4 2025), $21.8 million (Q3 2025), and -$1.7 million (Q2 2025) per Business Quant data.